Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Therapeutic vaccines and cancer: focus on DPX-0907.

Karkada M, Berinstein NL, Mansour M.

Biologics. 2014 Feb 10;8:27-38. doi: 10.2147/BTT.S55196. eCollection 2014. Review.

2.

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.

Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M.

J Transl Med. 2012 Aug 3;10:156. doi: 10.1186/1479-5876-10-156.

3.

A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.

Karkada M, Weir GM, Quinton T, Sammatur L, MacDonald LD, Grant A, Liwski R, Juskevicius R, Sinnathamby G, Philip R, Mansour M.

J Immunother. 2010 Apr;33(3):250-61. doi: 10.1097/CJI.0b013e3181c1f1e9.

PMID:
20445345
4.

Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration.

Karkada M, Quinton T, Blackman R, Mansour M.

ISRN Oncol. 2013;2013:753427. doi: 10.1155/2013/753427. Epub 2013 Mar 7.

5.
6.

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.

Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M.

Oncoimmunology. 2015 May 7;4(8):e1026529. eCollection 2015 Aug.

7.

Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.

Wang L, Xie Y, Ahmed KA, Ahmed S, Sami A, Chibbar R, Xu Q, Kane SE, Hao S, Mulligan SJ, Xiang J.

Breast Cancer Res Treat. 2013 Jul;140(2):273-84. doi: 10.1007/s10549-013-2626-7. Epub 2013 Jul 24.

PMID:
23881522
8.

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA.

Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23.

PMID:
9815296
10.

A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.

Conforti A, Peruzzi D, Giannetti P, Biondo A, Ciliberto G, La Monica N, Aurisicchio L.

J Immunother. 2009 Sep;32(7):744-54. doi: 10.1097/CJI.0b013e3181aee1b6.

PMID:
19561534
11.

MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.

Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T, Hafner J, Philip M, Clay TM, Lyerly HK, Philip R.

Clin Cancer Res. 2011 May 15;17(10):3408-19. doi: 10.1158/1078-0432.CCR-10-2614. Epub 2011 Feb 7.

12.

Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.

Rüttinger D, van den Engel NK, Winter H, Schlemmer M, Pohla H, Grützner S, Wagner B, Schendel DJ, Fox BA, Jauch KW, Hatz RA.

J Transl Med. 2007 Sep 14;5:43.

13.

Peptide vaccines in breast cancer: The immunological basis for clinical response.

Peres Lde P, da Luz FA, Pultz Bdos A, Brígido PC, de Araújo RA, Goulart LR, Silva MJ.

Biotechnol Adv. 2015 Dec;33(8):1868-77. doi: 10.1016/j.biotechadv.2015.10.013. Epub 2015 Oct 30. Review.

PMID:
26523780
14.

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.

Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM.

Cancer Immunol Immunother. 2000 Dec;49(10):517-29.

PMID:
11129322
15.

Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.

Brill TH, Kübler HR, von Randenborgh H, Fend F, Pohla H, Breul J, Hartung R, Paul R, Schendel DJ, Gansbacher B.

J Gene Med. 2007 Jul;9(7):547-60.

PMID:
17514769
16.

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.

Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S.

Prostate. 2003 Sep 15;57(1):80-92.

PMID:
12886526
17.

Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines.

DeBay DR, Brewer KD, LeBlanc SA, Weir GM, Stanford MM, Mansour M, Bowen CV.

Mol Ther Methods Clin Dev. 2015 Dec 16;2:15048. doi: 10.1038/mtm.2015.48. eCollection 2015.

18.

Antitumor vaccination: where we stand.

Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S.

Haematologica. 2000 Nov;85(11):1172-206. Review.

19.

Cancer vaccines: an update with special focus on ganglioside antigens.

Bitton RJ, Guthmann MD, Gabri MR, Carnero AJ, Alonso DF, Fainboim L, Gomez DE.

Oncol Rep. 2002 Mar-Apr;9(2):267-76. Review.

PMID:
11836591
20.

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.

Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF.

Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72.

PMID:
10950151
Items per page

Supplemental Content

Write to the Help Desk